JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The prognostic model of low-grade glioma based on m6A-associated immune genes and functional study of FBXO4 in the tumor microenvironment

  • 0Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Peerj +

|

March 25, 2025

|

March 25, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a prognostic model for low-grade glioma (LGG) that effectively predicts patient survival and links it to the tumor immune microenvironment. FBXO4 is identified as a potential biomarker for LGG diagnosis and prognosis.

Area Of Science

  • Oncology
  • Immunology
  • Molecular Biology

Background

  • N6-methyladenosine (m6A) modification influences oncogene and tumor suppressor gene expression, impacting tumorigenesis.
  • The immune system plays a critical role in tumor development, therapy, and resistance.
  • Limited research exists on m6A-related immune markers in low-grade gliomas (LGG).

Purpose Of The Study

  • To develop and validate a prognostic model for LGG based on m6A regulatory and immune genes.
  • To investigate the relationship between m6A scores and the tumor immune microenvironment in LGG.
  • To explore the biological role of FBXO4 in glioma cells.

Main Methods

  • Utilized data from the Chinese Glioma Genome Atlas and The Cancer Genome Atlas databases.
  • Constructed a prognostic model using univariate Cox, LASSO, and multivariate Cox regression analyses.
  • Performed clustering analyses to group samples by m6A and immune gene expression, followed by correlation analysis and in vitro experiments (qRT-PCR, proliferation, migration assays).

Main Results

  • The prognostic model demonstrated strong predictive performance (AUC > 0.9 in training, 0.623–0.894 in validation groups).
  • High expression of m6A regulatory and immune genes correlated with increased immune cells, lower tumor purity, and poorer survival.
  • The m6A score positively correlated with immune cell types and was associated with specific signaling pathways; FBXO4 silencing inhibited glioma cell proliferation and migration.

Conclusions

  • The developed prognostic model effectively assesses LGG prognosis and its immune microenvironment.
  • m6A scores provide insights into the LGG tumor microenvironment and pathophysiology.
  • FBXO4 shows potential as a diagnostic and prognostic biomarker for LGG.

Keywords: